Anti-PARP1 antibody [Y17] - BSA and Azide free (ab284670)
Key features and details
- Rabbit monoclonal [Y17] to PARP1 - BSA and Azide free
- Suitable for: WB
- Knockout validated
- Reacts with: Human
- Isotype: IgG
Related conjugates and formulations
Overview
-
Product name
Anti-PARP1 antibody [Y17] - BSA and Azide free
See all PARP1 primary antibodies -
Description
Rabbit monoclonal [Y17] to PARP1 - BSA and Azide free -
Host species
Rabbit -
Specificity
This antibody is specific to PARP1. It should recognize the intact form (116kDa) and the p25 cleaved form of PARP1.
-
Tested applications
Suitable for: WBmore details
Unsuitable for: Flow Cyt,ICC/IF or IHC -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Jurkat and Camptothecin cell lysate.
-
General notes
ab284670 is the carrier-free version of ab32378
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. -
Storage buffer
pH: 7.2
Constituent: 100% PBS -
Carrier free
Yes -
Concentration information loading...
-
Clonality
Monoclonal -
Clone number
Y17 -
Isotype
IgG -
Research areas
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab284670 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use at an assay dependent concentration. Predicted molecular weight: 113 kDa.
|
Notes |
---|
WB
Use at an assay dependent concentration. Predicted molecular weight: 113 kDa. |
Target
-
Function
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. Mediates the poly(ADP-ribosyl)ation of APLF and CHFR. Positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. -
Sequence similarities
Contains 1 BRCT domain.
Contains 1 PARP alpha-helical domain.
Contains 1 PARP catalytic domain.
Contains 2 PARP-type zinc fingers. -
Post-translational
modificationsPhosphorylated by PRKDC. Phosphorylated upon DNA damage, probably by ATM or ATR.
Poly-ADP-ribosylated by PARP2. Poly-ADP-ribosylation mediates the recruitment of CHD1L to DNA damage sites.
S-nitrosylated, leading to inhibit transcription regulation activity. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 142 Human
- Omim: 173870 Human
- SwissProt: P09874 Human
- Unigene: 177766 Human
-
Alternative names
- ADP ribosyltransferase (NAD+; poly (ADP ribose) polymerase) antibody
- ADP ribosyltransferase antibody
- ADP ribosyltransferase diphtheria toxin like 1 antibody
see all
Images
-
This data was developed using ab32378, the same antibody clone in a different buffer formulation.
Lane 1: Wild type HAP1 whole cell lysate (20 µg)
Lane 2: PARP1 knockout HAP1 whole cell lysate (20 µg)
Lane 3: HeLa whole cell lysate (20 µg)
Lane 4: MCF7 whole cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab32378 observed at 125 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab32378 was shown to specifically react with PARP1 when PARP1 knockout samples were used. Wild-type and PARP1 knockout samples were subjected to SDS-PAGE. Ab32378 and ab8245 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/10000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) ab216773 and 680CW Goat anti Mouse secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.
-
All lanes : Anti-PARP1 antibody [Y17] (ab32378) at 1/1000 dilution
Lane 1 : Jurkat cell lysate.
Lane 2 : Jurkat and Camptothecin cell lysate.
Predicted band size: 113 kDa
Observed band size: 115 kDa why is the actual band size different from the predicted?This data was developed using ab32378, the same antibody clone in a different buffer formulation.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
Certificate of Compliance
References (0)
ab284670 has not yet been referenced specifically in any publications.